研究设计与统计

订阅

MedSci主页 / 所有栏目 / 研究设计与统计

什么是 Kendall 的一致性系数 (KCC)？

2019-10-15 不详 网络

一致性Kendall
关注

什么是 Kendall 的一致性系数 (KCC)？ Kendall 的一致性系数表示在评估相同样本时多名评估员所做顺序评估的关联程度。Kendall 系数常用于属性一致性分析。 解释 Kendall 一致性系数值 Kendall 系数值介于 0 和 1 之间。Kendall 值越大，关联程度约强。一般而言，当 Kendall 系数为 0.9 或以上时，就认为关联程度很好。较高或显

什么是 Kendall 的一致性系数 (KCC)？ Kendall 的一致性系数表示在评估相同样本时多名评估员所做顺序评估的关联程度。Kendall 系数常用于属性一致性分析。解释 Kendall 一致性系数值Kendall 系数值介于 0 和 1 之间。Kendall 值越大，关联程度约强。一般而言，当 Kendall 系数为 0.9 或以上时，就认为关联程度很好。较高或显著的 Kendall 系数意味着检验员评估样本时采用的是基本一致的标准。什么是 Kendall 的相关系数？如果为每个样本提供一个已知评级，Minitab 还将计算 Kendall 的相关系数。这些相关系数将提供给每位检验员以确定每位检验员与已知标准的一致性；而总体系数表示所有检验员与标准的一致性。相关系数有助于确定某位检验员是否保持了一致性但却不准确。解释 Kendall 的相关系数Kendall 的系数值可以从 −1 变化到 1。正值表示正向关联。负值表示负向关联。值越大，关联程度越强。根据您的样本数据，使用 Kendall 相关系数和它们的 p 值在两个对立假设之间选择：H0：所有评估员的评级和已知标准之间没

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2036898, encodeId=524a203689882, content=<a href='/topic/show?id=951f1045810' target=_blank style='color:#2F92EE;'>#Kendall#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10458, encryptionId=951f1045810, topicName=Kendall)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Feb 28 19:06:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906933, encodeId=8b92190693332, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Mon Aug 10 17:06:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329291, encodeId=a8261329291ef, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Oct 17 05:06:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581064, encodeId=05f7158106419, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12600, encryptionId=3beb12600e5, topicName=NDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a9e16702381, createdName=12498a49m65暂无昵称, createdTime=Thu Oct 17 05:06:00 CST 2019, time=2019-10-17, status=1, ipAttribution=)]
    2020-02-28 xre2008

    #Kendall#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2036898, encodeId=524a203689882, content=<a href='/topic/show?id=951f1045810' target=_blank style='color:#2F92EE;'>#Kendall#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10458, encryptionId=951f1045810, topicName=Kendall)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Feb 28 19:06:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906933, encodeId=8b92190693332, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Mon Aug 10 17:06:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329291, encodeId=a8261329291ef, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Oct 17 05:06:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581064, encodeId=05f7158106419, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12600, encryptionId=3beb12600e5, topicName=NDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a9e16702381, createdName=12498a49m65暂无昵称, createdTime=Thu Oct 17 05:06:00 CST 2019, time=2019-10-17, status=1, ipAttribution=)]
    2020-08-10 zhanfl

    #一致性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2036898, encodeId=524a203689882, content=<a href='/topic/show?id=951f1045810' target=_blank style='color:#2F92EE;'>#Kendall#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10458, encryptionId=951f1045810, topicName=Kendall)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Feb 28 19:06:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906933, encodeId=8b92190693332, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Mon Aug 10 17:06:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329291, encodeId=a8261329291ef, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Oct 17 05:06:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581064, encodeId=05f7158106419, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12600, encryptionId=3beb12600e5, topicName=NDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a9e16702381, createdName=12498a49m65暂无昵称, createdTime=Thu Oct 17 05:06:00 CST 2019, time=2019-10-17, status=1, ipAttribution=)]
    2019-10-17 膀胱癌

    #ALL#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2036898, encodeId=524a203689882, content=<a href='/topic/show?id=951f1045810' target=_blank style='color:#2F92EE;'>#Kendall#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10458, encryptionId=951f1045810, topicName=Kendall)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Feb 28 19:06:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906933, encodeId=8b92190693332, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Mon Aug 10 17:06:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329291, encodeId=a8261329291ef, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Oct 17 05:06:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581064, encodeId=05f7158106419, content=<a href='/topic/show?id=3beb12600e5' target=_blank style='color:#2F92EE;'>#NDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12600, encryptionId=3beb12600e5, topicName=NDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a9e16702381, createdName=12498a49m65暂无昵称, createdTime=Thu Oct 17 05:06:00 CST 2019, time=2019-10-17, status=1, ipAttribution=)]
    2019-10-17 12498a49m65暂无昵称

    #NDA#

    0

相关资讯

不通过一致性评价注销批文？江苏药监**回应来了

6日，江苏省人民政府网站转载的本省省委机关报新华日报《我省清理仿制药市场，不通过一致性评价将注销批文》一文引起行业动荡。此文一出，瞬间刷了医药人的朋友圈，而文中引用的是江苏省药监局注册处处长王宗敏的描述，另外又被江苏省人民政府官网转发，在多重官方的背书之下，医药行业人士及诸多媒体认为这是一个信号，或者国家层面在大限来临前又有新动作。对此，E药经理人分别就此向国家药监局、江苏省药监局王宗敏做了

定了！289品种年底未通过一致性评价 直接淘汰！

终于来了，289品种年底未通过一致性评价直接淘汰！

未过一致性评价均不再采购 千家药企受影响

未过一致性评价药企，迎来最大冲击。辽宁省发文，只要药品未过一致性评价，原则上均暂停采购，注意没有过一致性评价药企已达3家的限定！

重磅！一致性评价年末大限取消

国家药监局正式发文，一致性评价年末大限，确定延期！

又一省 一致性评价药品特权落地

根据公告，该产品自公告之日起挂网执行。各采购联合体和各级医疗机构要将“ 通过一致性评价品种”纳入与原研药可相互替代药品目录，优先采购和使用 。

这省 未过一致性药品暂时安全了

四川就仿制药供应保障发文，未提及不再采购未过一致性评价品种。未过一致性评价药品究竟将走向何方？